Alex Spira, MD, PhD, FACP, Discusses Novel Agent in Multiple Tumor Types

June 17, 2020

An investigational PD-L1 PROBODY therapeutic, CX-072, demonstrated durable responses and appeared tolerable in patients across multiple tumor types.

An investigational PD-L1 PROBODY therapeutic, CX-072, demonstrated durable responses and appeared tolerable in patients across multiple tumor types, according to findings presented at the 2020 ASCO Virtual Program.

Researchers evaluated 0.3 to 10 mg/kg of CX-072 alone and in combination with 3 to 10 mg/kg of ipilimumab (Yervoy) every 3 weeks.

Disease control rates were 41% for those treated with CX-072 alone, compared with 37% treated with the combination regimen. CX-072 induced 10 partial responses, while the combination yielded 1 complete response and 4 partial responses.

No treatment-related adverse events led to death. The most common reason for discontinuation was disease progression.

Next, the combination regimen is being explored in a phase 2 study as a second-line treatment for patients with melanoma.

Alex Spira, MD, PhD, FACP, medical oncologist at Virginia Cancer Specialists (VCS) and chair of the US Oncology Research Executive Committee, spoke with CancerNetwork about the study findings and next steps for the agent.

Reference:

Thistlethwaite F, Naing A, Gil-Martin, et al. PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. J Clin Oncol. 2020;38:abstract 3005. doi:10.1200/JCO.2020.38.15_suppl.3005.